Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "OPKO Health Reference Laboratories" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about OPKO Health Reference Laboratories for you to read. Along with our medical data and news we also list OPKO Health Reference Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of OPKO Health Reference Laboratories Companies for you to search.
NEW YORK, Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of OPKO Health ("OPKO" or the "Company") (NASDAQ: OPK). Such investors are advised to contact ...
NEW YORK, NY / ACCESSWIRE / May 22, 2018 / Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. ("OPKO" or the "Company") (NASDAQ: OPK). Such investors are advised to ...
OPKO Health has completed enrolment in a global pivotal Phase lll trial of somatrogon (hGH-CTP) for the treatment of growth...Read More... The post OPKO Health completes enrolment in Phase lll trial of somatrogon appeared first on Drug Development Technology.
OPKO Health (NASDAQ:OPK) reports financial results and business highlights for the three months ended March 31, 2018. As quoted in the press release: “We are pleased to report steady sequential-quarter growth for RAYALDEE and 4Kscore, as well as improvement in our lab business from Q4 of last year,” said Phillip Frost, Chairman and Chief Executive Officer of … Continued The post OPKO H...
Science and technology company, Merck, has entered into an agreement with HistoCyte Laboratories, for the distribution of its portfolio of cell line reference products for immunohistochemistry and in situ hybridisation.
SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in OPKO Health, Inc. (NASDAQ: OPK) to the firm's investigation into Read more...
The SEC announced the charges Friday, alleging the Opko CEO and nine others manipulated stock prices in "classic pump-and-dump schemes."
The company has used multi-dose disposable pen to deliver an investigational long-acting human growth hormone product, somatrogon. Somatrogon is a new molecular entity, which maintains the natural sequence The post Opko Health completes enrollment in phase 3 study of somatrogon in GHD children appeared first on Compelo Medical Devices.
OPKO Health, Inc. (NASDAQ: OPK) is pleased to confirm that The Nasdaq Stock Market has lifted the trading suspension of OPKO’s shares. As noted previously, OPKO and 19 other defendants, including Dr. Phillip Frost, its CEO and Chairman, were named in a Complaint filed on September 7 by the Securities and Exchange Commission (“SEC”). The Comp...
OPKO Health, Inc. (NASDAQ:OPK) has had trading in its common stock halted by The Nasdaq Stock Market, and the exchange has advised OPKO that the halt will continue until the company responds (to Nasdaq’s satisfaction) to the exchange’s request for information related to the previously reported lawsuit filed by the U.S. Securities and Exchange Commissio...
OPKO Health, Inc. (NASDAQ: OPK) provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today. “OPKO learned today that the Securities and Exchange Commission has filed a lawsuit in the Southern District of New York against a number of individuals and entities, including OPKO and its CEO and Cha...
[Articles] Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
With the present study, we provide a robust, flexible forecasting platform from which reference forecasts and alternative health scenarios can be explored in relation to a wide range of independent drivers of health. Our reference forecast points to overall improvements through 2040 in most countries, yet the range found across better and worse health scenarios renders a precarious vision of the f...
Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up...
Merck, a leading science and technology company, has announced that it has entered into an agreement with HistoCyte Laboratories Ltd, Tyne, U.K., to be the exclusive multinational distributor of the company’s portfolio of cell line reference products for immunohistochemistry and in situ hybridization....
OPKO Health Inc. (OPK) has reported better-than-expected financial results for the first quarter ended March 31, 2018.
The science and technology company will be the exclusive multinational distributor of the company's portfolio of cell line reference products
Teva jumps, Opko rebounds – https://ift.tt/2xpbDHq
LabCorp, one of the nation’s two largest reference labs in the U.S., is investigating a security breach that could have put health records of millions of patients at risk (see: LabCorp Investigates a Possible Data Breach). The company, in a filing with the Securities and Exchange Commission, says it detected...
One week after pharmaceutical billionaire Phillip Frost was accused by the Securities and Exchange Commission of participating in a "pump-and-dump" scheme, the 81-year-old Opko Health CEO has released a statement denying the allegations against him.
Pharmacy Benefit Managers (PBMs) claim to keep drug costs under control, but their convoluted business models and tactics don’t always result in the best deal for employers. Reference based drug pricing is an interesting alternative approach. It’s used for drug cost control in other parts of the world and within the US for things like Read More The post Reference based pricing for phar...